Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ICU MedicalSTU:IC7 80 Net Margin % is 3.46% as of Jun. 2026, which is 6% below its 10-year median of 3.69. GuruFocus rates STU:IC7 with a GF Score™ of 80/100 and a GF Value™ of €105.79 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 815 Medical Devices & Instruments companies, ICU Medical ranks worse than 51.53% on this metric.
Net margin is calculated as Net Income divided by its Revenue. ICU Medical's Net Income for the
three
months ended in Jun. 2026 was €17 Mil. ICU Medical's Revenue for the
three
months ended in Jun. 2026 was €479 Mil. Therefore, ICU Medical's net margin for the quarter that ended in Jun. 2026 was 3.46%.
The historical rank and industry rank for ICU Medical's Net Margin % or its related term are showing as below:
STU:IC7'
s Net Margin % Range Over the Past 10 Years
Min: -4.94 Med: 3.69 Max: 16.63
Current: 1.39
STU:IC7's Net Margin % is ranked worse than 51.53% of 815
companies
in the Medical Devices & Instruments industry
Industry Median: 2.13
vs STU:IC7: 1.39
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
ICU Medical Net Margin % Related Terms
ICU Medical Net Margin % Historical Data
* Premium members only.
The historical data trend for ICU Medical's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:IC7 vs NVST, MMSI, MMED: Net Margin % Comparison
For the Medical Instruments & Supplies subindustry, ICU Medical's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ICU Medical Net Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ICU Medical's Net Margin % distribution charts can be found below:
* The bar in red indicates where ICU Medical's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ICU Medical (STU:IC7) has a Net Margin % of 3.46% as of Jun. 2026. Net margin is the ratio of total net income to net sales. View historical data on ICU Medical and its competitors. This is near median its historical median of 3.69. According to the industry distribution chart, ICU Medical ranks #420 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 51.5%.
Is ICU Medical's Net Margin % too high?
ICU Medical's current Net Margin % of 3.46% is near median its 10-year median of 3.69. The Medical Devices & Instruments industry median Net Margin % is 2.13. ICU Medical's value of 3.46% is 62.4% above this industry median. Based on the distribution chart, ICU Medical ranks #420 out of 815 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, ICU Medical has a GF Score™ of 80/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ICU Medical's Net Margin % compare to NVST and MMSI?
According to the Medical Devices & Instruments industry distribution chart, ICU Medical ranks #420 out of 815 companies for Net Margin %. This places ICU Medical in the lower half of its industry. The industry median Net Margin % is 2.13. ICU Medical's value of 3.46% is 62.4% above this benchmark. While the company's 10-year median is 3.69 vs. the industry median of 2.13, ICU Medical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Devices & Instruments company?
The median Net Margin % among Medical Devices & Instruments companies is 2.13, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ICU Medical's current Net Margin % of 3.46% is 62.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on ICU Medical and its competitors. For the Medical Devices & Instruments industry, the median Net Margin % is 2.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ICU Medical's current Net Margin % is 3.46%, which is near median its own 10-year median of 3.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ICU Medical stock overvalued right now?
Based on GuruFocus' analysis, ICU Medical (STU:IC7) is currently considered Significantly Overvalued. The stock's GF Value™ is €105.79, compared to a current price of €158.00 — trading 49.4% above its estimated fair value. The current Net Margin % is 3.46%, which is near median its 10-year median of 3.69 and 62.4% above the Medical Devices & Instruments industry median of 2.13. ICU Medical's overall GF Score™ is 80/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For ICU Medical (STU:IC7), the current Net Margin % is 3.46% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ICU Medical (STU:IC7) Overvalued in 2026?
Based on GuruFocus' analysis, ICU Medical stock appears to be overvalued.
The current stock price of €158.00 is trading 49.4% above its estimated GF Value™ of €105.79.
GuruFocus considers ICU Medical to be Significantly Overvalued.
Key valuation signals for STU:IC7:
Net Margin %: 3.46% (near median its 10-year median of 3.69)
GF Value™: €105.79 vs. price of €158.00 (49.4% above fair value)
Industry Position: 62.4% above the Medical Devices & Instruments median (#420 of 815)
No single metric tells the full story. See the STU:IC7 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.
80GF Score
Get the complete analysis for STU:IC7
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:IC7 has been successfully added to your 
